292 related articles for article (PubMed ID: 28956459)
21. [Efficacy and safety of intravenous itraconazole in different antifungal strategies for patients undergoing intensive chemotherapy or hematopoietic stem cell transplantation].
Ji Y; Xu L; Huang X
Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):689-93. PubMed ID: 25152113
[TBL] [Abstract][Full Text] [Related]
22. Treatment of invasive fungal diseases in cancer patients-Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).
Ruhnke M; Cornely OA; Schmidt-Hieber M; Alakel N; Boell B; Buchheidt D; Christopeit M; Hasenkamp J; Heinz WJ; Hentrich M; Karthaus M; Koldehoff M; Maschmeyer G; Panse J; Penack O; Schleicher J; Teschner D; Ullmann AJ; Vehreschild M; von Lilienfeld-Toal M; Weissinger F; Schwartz S
Mycoses; 2020 Jul; 63(7):653-682. PubMed ID: 32236989
[TBL] [Abstract][Full Text] [Related]
23. Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals.
Heimann SM; Penack O; Heinz WJ; Rachow T; Egerer G; Kessel J; Claßen AY; Vehreschild JJ
Int J Infect Dis; 2019 Jun; 83():130-138. PubMed ID: 30978465
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry.
Vehreschild JJ; Sieniawski M; Reuter S; Arenz D; Reichert D; Maertens J; Böhme A; Silling G; Martino R; Maschmeyer G; Rüping MJ; Ullmann AJ; Cornely OA
Int J Antimicrob Agents; 2009 Nov; 34(5):446-50. PubMed ID: 19700265
[TBL] [Abstract][Full Text] [Related]
25. Clinical study on empirical and diagnostic-driven (pre-emptive) therapy of voriconazole in severe aplastic anaemia patients with invasive fungal disease after intensive immunosuppressive therapy.
Wu Y; Yan L; Wang H; Liu H; Xing L; Fu R; Shao Z
Eur J Clin Microbiol Infect Dis; 2021 May; 40(5):949-954. PubMed ID: 33219473
[TBL] [Abstract][Full Text] [Related]
26. Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients: A retrospective observational study.
Chen X; Wang J; Wang S; Jin J; Li J; Gao S; Li J; Li J; Liu Q; Hu Y; Lin D; Sun Z; Yang J; Hu J; Wu X; Huang X; Shao Z; Deng Q; Wang C; Liu L; Chen H; Wang J; Wei X; Shen J; Zhang X; Wu D
Medicine (Baltimore); 2021 Jul; 100(30):e26772. PubMed ID: 34397725
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology and risk factors for invasive fungal disease in liver transplant recipients in a tertiary transplant center.
Lum L; Lee A; Vu M; Strasser S; Davis R
Transpl Infect Dis; 2020 Dec; 22(6):e13361. PubMed ID: 32510755
[TBL] [Abstract][Full Text] [Related]
29. Invasive Fungal Infection in Febrile Patients with Hematologic Malignancies Undergoing Chemotherapy in Iran.
Sheikhbahaei S; Mohammadi A; Sherkat R; Naeini AE; Yaran M; Najafi S
Endocr Metab Immune Disord Drug Targets; 2019; 19(3):302-307. PubMed ID: 30747087
[TBL] [Abstract][Full Text] [Related]
30. Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study.
Candoni A; Caira M; Cesaro S; Busca A; Giacchino M; Fanci R; Delia M; Nosari A; Bonini A; Cattaneo C; Melillo L; Caramatti C; Milone G; Scime' R; Picardi M; Fanin R; Pagano L;
Mycoses; 2014 Jun; 57(6):342-50. PubMed ID: 24373120
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Caspofungin in Unclassified Invasive Fungal Infection Cases: A Retrospective Analysis of Patients with Hematological Malignancies in China.
Zhang X; Hu J; Hu Y; Huang H; Jin J; Li J; Liu Q; Shao Z; Wang J; Wang Q; Wu D; Huang X
Med Sci Monit; 2018 Jul; 24():5258-5270. PubMed ID: 30056458
[TBL] [Abstract][Full Text] [Related]
32. EPICO 3.0. Empirical antifungal therapy in critically-ill hematology patients.
Llinares P; Ruiz I; Zaragoza R; Ferrer R; Rodríguez AH; Maseda E; Grau S;
Rev Iberoam Micol; 2016; 33(4):206-215. PubMed ID: 27751781
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy and Safety of Low-dose Amphotericin B in Different Antifungal Strategies for Treatment of Invasive Fungal Disease in Patients with Hematological Malignancies].
Yang L; Jin XS; Li JH; Liu J; Guan W; Gao HH; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):221-225. PubMed ID: 28245405
[TBL] [Abstract][Full Text] [Related]
34. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies.
Hoenigl M; Strenger V; Buzina W; Valentin T; Koidl C; Wölfler A; Seeber K; Valentin A; Strohmeier AT; Zollner-Schwetz I; Raggam RB; Urban C; Lass-Flörl C; Linkesch W; Krause R
J Antimicrob Chemother; 2012 Aug; 67(8):2029-33. PubMed ID: 22566591
[TBL] [Abstract][Full Text] [Related]
35. Primary antifungal prophylaxis: decrease of invasive fungal disease incidence and reduction of risk factors in haematological patients in a 5-year retrospective study.
Li Y; Liu M; Zhai B; Zhao X; Wang L; Li H; Wang S; Zhu H; Wang Q; Gao C; Huang W; Yu L
Intern Med J; 2018 Jun; 48(6):713-720. PubMed ID: 29230923
[TBL] [Abstract][Full Text] [Related]
36. Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia.
Fung M; Kim J; Marty FM; Schwarzinger M; Koo S
PLoS One; 2015; 10(11):e0140930. PubMed ID: 26554923
[TBL] [Abstract][Full Text] [Related]
37. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study.
Lerolle N; Raffoux E; Socie G; Touratier S; Sauvageon H; Porcher R; Bretagne S; Bergeron A; Azoulay E; Molina JM; Lafaurie M
Clin Microbiol Infect; 2014 Nov; 20(11):O952-9. PubMed ID: 24861577
[TBL] [Abstract][Full Text] [Related]
38. Pediatric Antifungal Prescribing Patterns Identify Significant Opportunities to Rationalize Antifungal Use in Children.
Ferreras-Antolín L; Irwin A; Atra A; Chapelle F; Drysdale SB; Emonts M; McMaster P; Paulus S; Patel S; Rompola M; Vergnano S; Whittaker E; Warris A
Pediatr Infect Dis J; 2022 Mar; 41(3):e69-e74. PubMed ID: 34784303
[TBL] [Abstract][Full Text] [Related]
39. Baseline cytokine profiling identifies novel risk factors for invasive fungal disease among haematology patients undergoing intensive chemotherapy or haematopoietic stem cell transplantation.
Ceesay MM; Kordasti S; Rufaie E; Lea N; Smith M; Wade J; Douiri A; Mufti GJ; Pagliuca A
J Infect; 2016 Sep; 73(3):280-8. PubMed ID: 27343564
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial.
Santolaya ME; Alvarez AM; Acuña M; Avilés CL; Salgado C; Tordecilla J; Varas M; Venegas M; Villarroel M; Zubieta M; Farfán M; de la Maza V; Vergara A; Valenzuela R; Torres JP
J Antimicrob Chemother; 2018 Oct; 73(10):2860-2866. PubMed ID: 30010931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
